	US 11,708,421 B2
	Modular platform for targeted therapeutics
Ranit Kedmi, Tel-Aviv (IL); Nuphar Veiga, Yakum (IL); Itai Benhar, Rehovot (IL); and Dan Peer, Kiryat-Ono (IL)
Assigned to Ramot at Tel-Aviv University Ltd., Tel-Aviv (IL)
Appl. No. 16/316,629
Filed by Ramot at Tel-Aviv University Ltd., Tel-Aviv (IL)
PCT Filed Jul. 18, 2017, PCT No. PCT/IB2017/054334 § 371(c)(1), (2) Date Jan. 10, 2019, PCT Pub. No. WO2018/015881, PCT Pub. Date Jan. 25, 2018.
Claims priority of provisional application 62/363,417, filed on Jul. 18, 2016.
Prior Publication US 2019/0309087 A1, Oct. 10, 2019
Int. Cl. C07K 16/30 (2006.01); A61K 47/54 (2017.01); A61K 9/127 (2006.01); C07K 16/28 (2006.01); C07K 16/42 (2006.01); C12N 15/11 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/30 (2013.01) [A61K 9/127 (2013.01); A61K 47/543 (2017.08); A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C07K 16/2812 (2013.01); C07K 16/2815 (2013.01); C07K 16/2845 (2013.01); C07K 16/2866 (2013.01); C07K 16/2896 (2013.01); C07K 16/4241 (2013.01); C12N 15/11 (2013.01); C12N 15/111 (2013.01); C12N 2320/32 (2013.01)]

12 Claims

1. An immunoparticle comprising a lipidated secondary antibody comprising a secondary antibody attached via a linker to a lipidated peptide comprising an inner membrane lipidation signal, said lipidated secondary antibody is non-covalently attached to an outer surface of a synthetic lipid-based nanoparticle comprising synthetic lipids via said lipidated peptide, and attached to a primary antibody via an antigen recognition domain of said secondary antibody, wherein said secondary antibody has specificity for said primary antibody.